![]() ![]() While the task ahead may be daunting, the payoffs for public health could be significant. The current challenge for public-health authorities is how to combine insights from the first two years of the pandemic with analysis and actions to produce more robust national and regional vaccine ecosystems for future pandemics and epidemics.ĭecision makers could set the stage for vaccine resilience by defining what their countries and regions need assessing the local capacity to scale production of vaccine doses identifying gaps and weaknesses in their national and regional vaccine value chains (across multiple technology platforms, such as mRNA and viral vectors) building coordination capabilities and identifying and sizing the strategic investments required. Vaccine production capacity has expanded significantly, and many countries have started to reverse previous trends toward offshoring. But the developmental paths of the major COVID-19 vaccines suggest that future vaccines can achieve a radically shortened time to market if there are many candidates and modalities to work with. ![]() There are no safe bets in vaccine development-and our analysis shows that investments have abated following the surge of capital during the initial COVID-19 crisis, in 2020–21. For more, see “Fact sheet: President Biden to launch a National Biotechnology and Biomanufacturing Initiative,” The White House, September 12, 2022. 4 The United States has launched an initiative focused on manufacturing in biotechnology. The US government, for example, recently launched an initiative aimed at ensuring that biotechnology manufacturing capabilities are available in the country. This suggests that creating more resilient vaccine ecosystems-ones that allow a country or region to develop and trade expertise and resources and collaborate with partners to secure enough vaccine doses when they need them-is likely to play a critical role in readiness in the future. shifting expectations of what is possible in development and manufacturing and highlighting immunization as a viable path to protect populations quickly. Offodile II, “Closing the global vaccine equity gap: Equitably distributed manufacturing,” Lancet, May 21, 2022, Volume 399, Number 10339. COVID-19 laid bare the gaps in the global vaccine supply, 3 Celynne A. Preparing for the next pandemic is a priority for many national public-health leaders and requires them to lay the groundwork to mount an effective vaccine response. ![]() 2 “WHO director-general declares the ongoing monkeypox outbreak a Public Health Emergency of International Concern,” WHO, Jnote: WHO is actively working with partners and experts around the world to rename monkeypox. the monkeypox outbreak has been declared a public-health emergency of international concern by the World Health Organization (WHO). Even as COVID-19 enters the endemic stage in the United States and Europe, 1 “ When will the COVID-19 pandemic end?,” McKinsey, July 28, 2022. Public-health crises have vaulted to the top of national agendas over the past two years. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |